Therapeutic potential of histamine H4 receptor agonists in triple-negative human breast cancer experimental model

British Journal of Pharmacology

Volumn 170, Issue 1, 2013, Pages 188-199

  Martinel Lamas, Diego J ^a   Croci, Maximo ^b   Carabajal, Eliana ^a   Crescenti, Ernesto J V ^b   Sambuco, Lorena ^b   Massari, Noelia A ^a   Bergoc, Rosa M ^a   Rivera, Elena S ^a   Medina, Vanina A ^a,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Institute of Immunooncology   (Argentina)

^c National Scientific and Technical Research Council ^*  (Argentina)

Author keywords

apoptosis; breast cancer; cell proliferation; clozapine; H4 receptor ligands; histamine; JNJ28610244

Indexed keywords

CLOZAPINE; CYCLINE; HISTAMINE; HISTAMINE AGONIST; HISTAMINE H4 RECEPTOR; JNJ 28610244; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; HISTAMINE H4 RECEPTOR GENE; HUMAN; HUMAN CELL; LUNG METASTASIS; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VASCULARIZATION; TUMOR VOLUME;

APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; CLOZAPINE; H4 RECEPTOR LIGANDS; HISTAMINE; JNJ28610244;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLOZAPINE; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTAMINE; HISTAMINE AGONISTS; HUMANS; INDOLES; MICE; MICE, NUDE; OXIMES; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881622189     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12137     Document Type: Article

References (44)

1. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. (2011). Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24: 157-167.
2. Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, et al. (2005). The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 11: 6807-6815.
3. Cricco G, Mohamad N, Sáez MS, Valli E, Rivera ES, Martín G, (2011). Histamine and breast cancer: a new role for a well known amine. In:, Gunduz M, (ed.). Breast Cancer-Carcinogenesis, Cell Growth and Signalling Pathways. InTech: Rijeka, pp. 611-634.
4. Cricco GP, Mohamad NA, Sambuco LA, Genre F, Croci M, Gutiérrez AS, et al. (2008). Histamine regulates pancreatic carcinoma cell growth through H3 and H4 receptors. Inflamm Res 57: S23-S24.
5. Darvas Z, Sakurai E, Schwelberger HG, Hegyesi H, Rivera E, Othsu H, et al. (2003). Autonomous histamine metabolism in human melanoma cells. Melanoma Res 13: 239-246.
6. Davio CA, Cricco GP, Andrade N, Bergoc RM, Rivera ES, (1993). H1 and H2 histamine receptors in human mammary carcinomas. Agents Actions 38: C172-C174.
7. De Esch JP, Thurmond RL, Jongejan A, Leurs R, (2005). The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 26: 462-469.
8. Fang Z, Yao W, Xiong Y, Li J, Liu L, Shi L, et al. (2011). Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression. BMC Cancer 11: 1-11.
9. Francis H, DeMorrow S, Venter J, Onori P, White M, Gaudio E, et al. (2012). Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut 61: 753-764.
10. Ghosh AK, Hirasawa N, Ohuchi K, (2001). Enhancement by histamine of vascular endothelial growth factor production in granulation tissue via H(2) receptors. Br J Pharmacol 134: 1419-1428.
11. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, et al. (1997). International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49: 253-284.
12. Huang JF, Thurmond RL, (2008). The new biology of histamine receptors. Curr Allergy Asthma Rep 8: 21-27.
13. Jasinski P, Terai K, Zwolak P, Dudek AZ, (2008). Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer 44: 1315-1322.
14. Jemal A, Siegel R, Xu J, Ward E, (2010). Cancer statistics. CA Cancer J Clin 60: 227-300.
15. Johansson M, Henriksson R, Bergenheim AT, Koskinen LO, (2000). Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br J Cancer 83: 826-832.
16. Kahlson G, Rosengren E, (1968). New approaches to the physiology of histamine. Physiol Rev 48: 155-196.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
18. Lemos B, Davio C, Gass H, Gonzalez P, Cricco G, Martin G, et al. (1995). Histamine receptors in human mammary gland, different benign lesions and mammary carcinomas. Inflamm Res 44: S68-S69.
19. Leurs R, Chazot PL, Shenton FC, Lim HD, de, Esch IJ, (2009). Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 157: 14-23.
20. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R, (2005). Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 314: 1310-1321.
21. Lim HD, Adami M, Guaita E, Werfel T, Smits RA, Esch IJ, et al. (2009). Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430. Br J Pharmacol 157: 34-43.
22. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
23. Massari NA, Medina VA, Martinel Lamas DJ, Cricco GP, Croci M, Sambuco L, et al. (2011). Role of H4 receptor in histamine-mediated responses in human melanoma. Melanoma Res 21: 395-404.
24. Medina V, Cricco G, Nuñez M, Martín G, Mohamad N, Correa-Fiz F, et al. (2006). Histamine-mediated signaling processes in human malignant mammary cells. Cancer Biol Ther 5: 1462-1471.
25. Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jiménez F, Massari N, et al. (2008). The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther 7: 28-35.
26. Medina VA, Rivera ES, (2010a). Histamine receptors and cancer pharmacology. Br J Pharmacol 61: 755-767.
27. Medina VA, Rivera ES, (2010b). Histamine as a potential adjuvant to immuno and radiotherapy for cancer treatment: discovering new functions for the oldest biogenic amine. Curr Immunol Rev 6: 357-370.
28. Medina VA, Brenzoni PG, Martinel Lamas DJ, Massari N, Mondillo C, Nunez MA, et al. (2011). Role of histamine H4 receptor in breast cancer cell proliferation. Front Biosci 18: 1042-1060.
29. Meng F, Han Y, Staloch D, Francis T, Stokes A, Francis H, (2011). The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Hepatology 54: 1718-1728.
30. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S, (2000). Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 275: 36781-36786.
31. Ohtsu H, Watanabe T, (2003). New functions of histamine found in histidine decarboxylase gene knockout mice. Biochem Biophys Res Commun 305: 443-447.
32. Perou CM, Sorlie T, Eisen MB, van de, Rijn M, Jeffrey SS, Rees CA, et al. (2000). Molecular portraits of human breast tumours. Nature 406: 747-752.
33. Põs Z, Hegyesi H, Rivera ES, (2004). Histamine and cell proliferation. In:, Falus A, (ed.). Histamine: Biology and Medical Aspects. Budapest: SpringMed Publishing, pp. 199-217.
34. Rakha EA, Chan S, (2011). Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol) 23: 587-600.
35. van Rijn RM, van Marle A, Chazot PL, Langemeijer E, Qin Y, Shenton FC, et al. (2008). Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor. Biochem J 414: 121-131.
36. Rivera ES, Cricco GP, Engel NI, Fitzsimons CP, Martín GA, Bergoc RM, (2000). Histamine as an autocrine growth factor: an unusual role for a widespread mediator. Semin Cancer Biol 10: 15-23.
37. Romero AI, Thoren FB, Aurelius J, Askarieh G, Brune M, Hellstrand K, (2009). Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 70: 194-205.
38. Sotiriou C, Neo S, McShane LM, Korn EL, Long PM, Jazaeri A, et al. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
39. Tiligada E, Zampeli E, Sander K, Stark H, (2009). Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 18: 1519-1531.
40. Tomita K, Izumi K, Okabe S, (2003). Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci 93: 321-330.
41. Vera I, Rezende L, Molina V, Sanz-Fuentenebro J, (2012). Clozapine as treatment of first choice in first psychotic episodes. What do we know? Actas Esp Psiquiatr 40: 281-289.
42. Yu F, Wolin RL, Wei J, Desai PJ, McGovern PM, Dunford PJ, et al. (2010). Pharmacological characterization of oxime agonists of the histamine H4 receptor. J Receptor Ligand Channel Res 3: 37-49.
43. Zampeli E, Tiligada E, (2009). The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 157: 24-33.
44. Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, et al. (2001). Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59: 434-441.